PVT 101
Alternative Names: PVT-101Latest Information Update: 18 Sep 2023
At a glance
- Originator Parvus Therapeutics
- Developer Novartis; Parvus Therapeutics
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Type 1 diabetes mellitus
Most Recent Events
- 05 Sep 2023 Early research in Type 1 diabetes mellitus in USA (unspecified route) (Parvus therapeutic pipeline, September 2023)
- 19 Apr 2017 Novartis acquires worldwide rights to use Parvus' navacim technology to develop and commercialise products for the treatment of type I diabetes
- 19 Apr 2017 Parvus Therapeutics and Novartis plans for IND filing for Type 1 diabetes